Seeking Alpha

An FDA advisory panel votes 20-2 in favor of recommending Vivus (VVUS) weight-loss drug Qnexa....

An FDA advisory panel votes 20-2 in favor of recommending Vivus (VVUS) weight-loss drug Qnexa. Shares still halted. (earlier)
From other sites
Comments (1)
  • Spencer Knight
    , contributor
    Comments (417) | Send Message
     
    Sequel study was worth the wait. Now it's time to focus on the full report to determine if the FDA will rule in line with the Ad Comm. This is a big short term win for VVUS; too bad it wasn't 22-0 though.
    22 Feb 2012, 04:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs